Clinical Implications
It is crucial for healthcare professionals to check serum phosphate levels prior to administering ferric carboxymaltose in patients at risk. This includes those who are receiving subsequent courses within three months. Any pre-existing hypophosphatemia should be corrected, and patients should be informed about the symptoms to watch for. In severe symptomatic or persistent cases, it may be necessary to consider permanent discontinuation of the treatment.
Understanding Risks
Fatigue and muscle weakness experienced after intravenous iron therapy might be incorrectly associated with ongoing iron deficiency anemia. However, the FDA has highlighted another potential issue: symptomatic hypophosphatemia linked to ferric carboxymaltose injections.
Regulatory Actions
The FDA has issued a boxed warning regarding this risk in the labeling of ferric carboxymaltose (Injectafer). Although this risk has been known since 2020, monitoring recommendations were reinforced in 2023 due to continued reports of symptomatic cases. Data from the FDA Sentinel indicated that less than 20% of patients receiving ferric carboxymaltose had serum phosphate levels tested.
Clinical Cases
Occurrences of hypophosphatemia have been reported following both single and multiple infusions; however, most serious postmarketing cases arise after repeated administration. Complications from these cases can include hospitalization, extended phosphate replacement, osteomalacia, and even fractures.
Patient Assessment
Prior to treatment, it is important for clinicians to evaluate potential risk factors such as gastrointestinal malabsorption, inflammatory bowel disease, vitamin D deficiency, malnutrition, hyperparathyroidism, hereditary hemorrhagic telangiectasia, and certain medications that could influence proximal renal tubular function. Any pre-existing hypophosphatemia must be managed before initiating treatment.
Patient Guidance
Patients should be advised to report any new or worsening symptoms such as fatigue, muscle weakness, bone or joint pain, confusion, seizures, or indications of cardiac arrhythmia. Hypophosphatemia should be treated based on clinical judgment, and if it is severe or symptomatic and does not resolve, the consideration of discontinuing ferric carboxymaltose should be made.
Disclaimer: The information provided is for educational purposes only and should not be considered medical advice. Always consult a healthcare professional for concerns regarding medical conditions and treatments.
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
